epocrates logo
epocrates logo
epocrates logo
  • 0

Journal Article Synopsis

MMWR

Skip, delay, quit: two in five GLP-1 users bend the Rx

November 17, 2026

card-image

Clinical takeaway: Ask patients on a GLP-1 how they are really taking it and what filling a prescription costs before interpreting any poor responses as treatment failure. About two in five users reported altering their prescribed regimen. 

Clinicians who prescribe a GLP-1 medication can lose sight of it once the prescription leaves their hands. Approvals for weight management, semaglutide in 2021 and tirzepatide in 2023, sent prescriptions climbing. But high prices, drug shortages and limited insurance coverage have followed. Compounded versions filled the gap during the shortages, though FDA does not review them for safety, effectiveness or quality before they are marketed. 

Little national data has existed on compounded use or on what patients do when those barriers hit. A cross-sectional CDC survey of US adults now puts numbers on both. 

About two in five GLP-1 users, or 44%, reported taking the medication differently from how it was prescribed. Skipped doses were the most common change at 28%. The count also included users who delayed fills or stopped entirely. 

Cost and availability were the reasons users cited most at 38% and 36% respectively, of those who changed their use. Adults aged 18 to 39 were nearly twice as likely as those 65 and older to report a change, likely given the role of Medicare. Cost weighed heaviest on the younger group, with 58% of younger changers naming it, versus 20% of those 65 and older. 

About one in five users reported taking a compounded version, and another 8.8% did not know whether theirs was compounded. Users on compounded versions reported changing their use more often, 62% versus 36% of other users. 

Data came from self-reported answers to the Rapid Surveys System, which draws on two online panels built from probability samples of US households. Responses collected in July and August 2025 were weighted to national population totals. Of 8,118 respondents, 976 reported taking a GLP-1 medication in the past year, and those users answered follow-up questions on compounded versions and on changes to their use. 

The barriers reached every age group: at least half of users who made changes in each age category cited cost or availability as a problem. The report frames that as an opportunity for clinicians and payers to learn more about patient experiences, including side effects. 

"Substantial prevalence of GLP-1 medication use highlights the expanded role of these medications in chronic disease pharmacotherapy," the authors said. "Modifications in GLP-1 medication use reflect, in part, responses to cost- and access-related challenges. Future research could evaluate the implications of real-world medication use, including dose and frequency adjustments, on safety and effectiveness." 

Source: Pierce SL, et al. (2026 Nov 12) MMWR. Use of Glucagon-Like Peptide-1 Medications and Modified Medication Use Among Adults — United States, 2025

learn more about epocrates plus

Clinical FAQs

Check out the answers to frequently asked questions about our clinical content.

Download Epocrates from the App StoreDownload Epocrates from the Play Store
About UsFeaturesBusiness SolutionsHelp & FeedbackCookie Preferences
© 2026 epocrates, Inc.   Terms of UsePrivacy PolicyEditorial PolicyDo Not Sell or Share My Information